4-(tert-butoxycarbonylamino)tetrahydropyran-3-carboxylic acid | 1785059-06-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: 4-(tert-butoxycarbonylamino)tetrahydropyran-3-carboxylic acid
• 英文别名: 4-{[(Tert-butoxy)carbonyl]amino}oxane-3-carboxylic acid；4-[(2-methylpropan-2-yl)oxycarbonylamino]oxane-3-carboxylic acid
• CAS: 1785059-06-4
• 化学式: C₁₁H₁₉NO₅
• 分子量: 245.276
• InChiKey: SOTPUAQTEIJGML-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  84.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(tert-butoxycarbonylamino)tetrahydropyran-3-carboxylic acid 在 氯化铵 、 三乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以49 %的产率得到tert-butyl N-(3-carbamoyltetrahydropyran-4-yl)carbamate
  参考文献：
  名称：

  [EN] PYRIDAZINONE DERIVATIVES USEFUL AS T CELL ACTIVATORS
  [FR] DÉRIVÉS DE PYRIDAZINONE UTILES EN TANT QU'ACTIVATEURS DE LYMPHOCYTES T

  摘要：

  Disclosed herein are oxime compounds having the structure of Formula (I'): or a pharmaceutically acceptable salt, solvate, hydrate, isomer, tautomer, racemate, or isotope thereof, wherein L1, L2, R1, R2, R3, R4, R7, n, and r are as defined herein. Pharmaceutical compositions comprising them, processes for preparing them and uses of them to treat or prevent diseases, disorders and conditions are also provided. The compounds are inhibitors of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ) and are useful in the treatment of diseases, disorders and conditions related to DGKα and / or DGKζ activity. In particular, the compounds are useful for treating viral infections and proliferative disorders, such as cancer.

  公开号：

  WO2023122778A1
• 作为产物：
  描述：

  methyl 4-(tert-butoxycarbonylamino)tetrahydropyran-3-carboxylate 在 水 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 以88 %的产率得到4-(tert-butoxycarbonylamino)tetrahydropyran-3-carboxylic acid
  参考文献：
  名称：

  [EN] PYRIDAZINONE DERIVATIVES USEFUL AS T CELL ACTIVATORS
  [FR] DÉRIVÉS DE PYRIDAZINONE UTILES EN TANT QU'ACTIVATEURS DE LYMPHOCYTES T

  摘要：

  Disclosed herein are oxime compounds having the structure of Formula (I'): or a pharmaceutically acceptable salt, solvate, hydrate, isomer, tautomer, racemate, or isotope thereof, wherein L1, L2, R1, R2, R3, R4, R7, n, and r are as defined herein. Pharmaceutical compositions comprising them, processes for preparing them and uses of them to treat or prevent diseases, disorders and conditions are also provided. The compounds are inhibitors of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ) and are useful in the treatment of diseases, disorders and conditions related to DGKα and / or DGKζ activity. In particular, the compounds are useful for treating viral infections and proliferative disorders, such as cancer.

  公开号：

  WO2023122778A1

文献信息

• SULFONAMIDE DERIVATIVE AND USE THEREOF
  申请人：Fukumoto Shoji

  公开号：US20140024650A1

  公开（公告）日：2014-01-23

  Provided is a compound having an AMPA receptor function enhancing action, and useful as a prophylactic or therapeutic drug for depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. A compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a salt thereof.

  提供了一种具有AMPA受体功能增强作用的化合物，可用作预防或治疗抑郁症、阿尔茨海默病、精神分裂症、注意力缺陷多动障碍（ADHD）等药物。该化合物由式（I）表示：其中每个符号如本说明书所定义，或其盐。
• [EN] SULFONAMIDE DERIVATIVE AND USE THEREOF<br/>[FR] DÉRIVÉ DE SULFONAMIDE ET SON UTILISATION
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2012137982A9

  公开（公告）日：2013-02-14
• US9527807B2
  申请人：——

  公开号：US9527807B2

  公开（公告）日：2016-12-27